explore -WSS

explore

author：entertainment 2025-09-30 12:11:15 - browse：8

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： eGenesis tests gene

WSS

ER docs worry over extreme heat as a 'mass casualty event'

Study: Hearing aids may slow cognitive decline in those at risk

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

What we know about the American soldier detained in North Korea

UK homeowners get some respite as inflation falls by more than anticipated to a 15

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Wikipedia

explore

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The tragedy of Johnson & Johnson’s Covid vaccine

Bright Health sells Medicare Advantage business to Molina

eGenesis tests gene

Duchenne breakthrough therapy leaves behind pioneering families

NIH director takes cautious approach to Biden drug pricing priority

Apple is now the first public company to be valued at $3 trillion

FDA seeking to stop procedures at two unregulated stem cell clinics

Virginia high school admissions case could be legal follow

A look at other Americans who have crossed into North Korea over the years

Wikipedia

Why you get paid to donate plasma but not blood

Johnson & Johnson sues to stop Medicare negotiation

Biden administration sends mixed signals on US soldier who crossed into North Korea

How digital therapeutics firms are pivoting after Pear's bankruptcy

Prior authorization will have to move faster under new Biden rule

The surgeon had a dilemma only a Nazi medical text could resolve

Wikipedia

hotspot

hotspot

focus